ArticleMedicine2026
The association between sodium-glucose cotransporter 2 inhibitor and risk of pancreatic cancer among patients with type 2 diabetes mellitus: A real-world cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is one of the deadliest cancers, with limited screening options and a high mortality rate. Sodium-glucose cotransporter 2 inhibitors (SGLT2-i), a novel class of antidiabetic agents for type 2 diabetes mellitus (T2DM), have shown various benefits, but their long-term impact on PC risk is unclear. We conducted a real-world analysis using the TriNetX database, which aggregates de-identified electronic medical records from over 147 million patients across 120 health care organizations in 17 countries. We created 2 cohorts from 7,788,779 patients with newly diagnosed T2DM. One cohort received SGLT2-i, while the other received dipeptidyl peptidase 4 inhibitors (DPP4-i) as an active comparator. Patients were matched for demographics, comorbidities, serum hemoglobin A1c levels, and antidiabetic drug use. The primary outcome was the relative risk (RR) of PC over a 10-year follow-up. SGLT2-i use was associated with a significantly lower risk of PC compared to DPP4-i use (RR = 0.67; 95% CI = 0.613-0.731). Sensitivity analyses supported these findings across different follow-up periods: 3 years (RR = 0.805; 95% CI = 0.727-0.892) and 5 years (RR = 0.748; 95% CI = 0.682-0.82). Long-term SGLT2-i use in patients with T2DM was associated with a reduced risk of PC compared to DPP4-i use. These findings highlight the potential protective role of SGLT2-i against PC. Further studies, including randomized controlled trials, are warranted to clarify the causal relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.